Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: Case report and a review of the literature

Journal of Musculoskeletal Neuronal Interactions

Volumn 16, Issue 1, 2016, Pages 75-78

  Lampropoulou Adamidou, Kalliopi ^a   Tournis, S ^a   Triantafyllopoulos, I K ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adverse event; Atypical fracture; Bisphosphonates; Bone disease; Thalassemia

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ACCIDENTAL INJURY; ADULT; ARTICLE; ATYPICAL FEMORAL FRACTURE; BONE RADIOGRAPHY; BONE SCREW; CASE REPORT; CORTICAL THICKNESS (BONE); DRUG USE; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FRACTURE TREATMENT; HUMAN; INTRAMEDULLARY NAIL; INTRAMEDULLARY NAILING; LEFT TIBIAL MEDIAL CONDYLE FRACTURE; MALE; OBLIQUE FEMORAL SHAFT FRACTURE; OSTEOPOROSIS; PRACTICE GUIDELINE; REHABILITATION CARE; THALASSEMIA MAJOR; TIBIA FRACTURE; TREATMENT DURATION; BETA THALASSEMIA; CHEMICALLY INDUCED;

ADULT; BETA-THALASSEMIA; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS;

EID: 84960124475     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-46.
2. Cappellini MD. The Thalassemias. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine: Expert Consult - Online. 25 ed: Elsevier Health Sciences;2015:1089-95.
3. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009;33 Suppl 1:S46-57.
4. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27.
5. Giusti A. Bisphosphonates in the management of thalassemia- associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab 2014; 32:606-15.
6. Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 2010; 1202:237-43.
7. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8:96-110.
8. Chatterjee R, Bajoria R, Shah FT, Porter JB, Fedele S. High index of suspicion for early diagnosis of alendronateinduced stage zero osteonecrosis of jaw in thalassaemia major. Br J Haematol 2014;166:292-4.
9. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010;47:169-80.
10. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925;37:29-30.
11. Piomelli S. The management of patients with Cooley's anemia: transfusions and splenectomy. Semin Hematol 1995;32:262-8.
12. Vogiatzi MG, Macklin EA, Fung EB, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009;24:543-57.
13. Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with beta thalassemia major. Bone 2011;48:425-32.
14. Fung EB, Harmatz PR, Milet M, et al. Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 2008; 43:162-8.
15. Wong P, Fuller PJ, Gillespie MT, et al. Thalassemia bone disease: a 19-year longitudinal analysis. J Bone Miner Res 2014;29:2468-73.
16. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-39.
17. Tournis S, Dede AD, Savvidis C, Triantafyllopoulos IK, Kattamis A, Papaioannou N. Effects of teriparatide retreatment in a patient with beta-thalassemia major. Transfusion 2015.
18. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23.
19. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37.
20. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011; 22:2951-61.
21. Lampropoulou-Adamidou K, Tournis S, Balanika A, et al. Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration. Hormones (Athens) 2013;12:591-7.
22. Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011;96:1627-32.
23. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011;96:2675-80.
24. Stathopoulos IP, Liakou CG, Katsalira A, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens) 2011;10:280-91.
25. Fung EB, Vichinsky EP, Kwiatkowski JL, et al. Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 2011;48:1305-12.
26. Wong P, Fuller PJ, Gillespie MT, et al. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int 2013;24:1965-71.